Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers

Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial of Corfluvec Intranasal Vector Vaccine for the Prevention of COVID-19 in Healthy Volunteers Aged 18 to 60 Years

The aim of the study is to investigate the safety and immunogenicity of a two-component intranasal vaccine for the prevention of COVID-19 in healthy volunteers 18-60 years old

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Biological: Corfluvec component 1 low dose; Biological: Corfluvec component 2 low dose; Biological: Corfluvec component 1 high dose; Biological: Corfluvec component 2 high dose; Biological: Corfluvec low dose; Biological: Corfluvec high dose; Biological: Placebo

Detailed Description

Study include three parts. During the first part the two vaccine components will be administered separately to a small number of seronegative participants in low dose and then high dose to evaluate each component's safety. During the second part vaccine components would be administered one after another with 21 days interval to evaluate safety of the complete vaccine regimen (low dose and high dose). During the third part of the study the high dose vaccine will be administered to participants to evaluate vaccine immunogenicity. The whole study will include 200 participants. Duration of the study for each participant is about 6.5 months (no more than 194 days).

• Study Type: Interventional
• Enrollment (Actual): 200
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Russian Federation
  • Saint Petersburg, Russian Federation
    • Pavlov First State Medical University of St. Petersburg
  • Saint Petersburg, Russian Federation
    • Smorodintsev Research Institute of Influenza

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Availability of signed informed consent
2. Adult men and women aged 18-60
3. Diagnosed "healthy" according to the data of standard clinical, laboratory and instrumental examination methods, with the absence of clinically significant changes
4. Body Mass Index (BMI): 18.5≤ BMI ≤30 kg/m2
5. HI antibody titers ≤1:20 to influenza A/H1N1pdm09 and A/H3N2 (only for phase 1)
6. Serum antibodies to the SARS-CoV-2 N-protein not higher than 100 BAU/ml
7. The ability and willingness to make entries in the diary of self-observation, as well as to carry out all the visits foreseen in the study for control medical observation
8. Negative test for alcohol in exhaled air
9. Consent to use effective contraceptive methods throughout their participation in the study
10. Values of the complete blood count and biochemical blood analysis (during the screening) within 0.9*reference range lower limit and 1,1 * reference range upper limit
11. Negative tests for HIV, hepatitis B, hepatitis C, and syphilis

Exclusion Criteria:

1. Contact with COVID-19 patients within 14 days prior to the start of the clinical study
2. Positive rapid test result for SARS-CoV-2 antigen
3. Participation in another clinical study within three months prior to the start of the current study; planning to participate in another study during the current study period.
4. Immunization with any other non-study vaccine product, including COVID-19 vaccination within four weeks prior to enrollment in the current study, or refusal to postpone such until the end of the four-week period after completion of the current study
5. Regular use of nasal irrigation therapy during the last six months prior to enrollment in the current study or episodic use of the above method of treatment in the two weeks prior to the screening
6. History of frequent nosebleeds (>5) during the year prior to the current study
7. Clinically significant anatomic pathology or the presence of surgical intervention in the sinus area, paranasal sinuses, or traumatic injuries of the nose within a month before screening
8. Symptoms of acute respiratory disease, including fever, or other acute illness at the time of screening or within two weeks prior to screening
9. Treatment with immunoglobulins or other blood derived medications in the three months prior to screening or planning such treatment during the period of participation in the current study; donation of blood/plasma (450 ml or more) less than 2 months prior to screening
10. The presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions or continuous use (the drug was prescribed for more than 14 days without a break) of immunosuppressive drugs, immunomodulators for 6 months before the screening
11. History of bronchial asthma
12. Hypersensitivity and the presence of severe allergic reactions, including Quincke's edema, anaphylactic shock after the previous administration of any vaccine
13. History of wheezing after previous immunization with live influenza vaccine
14. Other adverse events after immunization (fever above 40°C, syncope, non-febrile convulsions, anaphylaxis) when there is a minimal likelihood that they are associated with a previous administration of any vaccine
15. Suspicion of hypersensitivity to any component of the study vaccine, including egg protein
16. Seasonal (in spring or autumn) increased sensitivity to the effects of natural factors
17. Acute or chronic clinically significant lung, cardiovascular, hepatic, endocrine, neurological, or psychiatric disorders, or impaired renal function identified by history, physical examination, or clinical laboratory findings that, in the opinion of the investigator, may influence the outcome of the study
18. History of leukemia or any other malignant diseases of the blood or solid malignant neoplasms of other organs
19. History of thrombocytopenic purpura or bleeding disorders
20. History of convulsions
21. The presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions, including HIV infection
22. Tuberculosis or residual changes after tuberculosis according to the anamnesis and / or available medical documentation
23. Chronic alcohol dependence or chronic use of illicit drugs, drug abuse
24. Claustrophobia and social phobia according to history and / or available medical records
25. For women of reproductive age - lactation, pregnancy or suspected pregnancy, early postpartum period
26. Premenopausal women (last menstrual period <1 year prior to signing informed consent) who are not surgically sterile and women who are of reproductive potential but do not use or plan to use valid birth control throughout the study and do not agree to perform a urine pregnancy test while participating in the study
27. Military personnel undergoing military service on conscription
28. Persons in custody in pre-trial detention centers and serving sentences in places of deprivation of liberty
29. Special diet (eg, vegetarian, vegan, salt-restricted) or lifestyle (night work, extreme physical activity)
30. Any condition that, in the opinion of the investigator, may increase the risk to the health of a volunteer participating in the study or affect the results of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

9

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 0a; Single dose of 7.2 lg EID50 of H3N2 vaccine component	Biological: Corfluvec component 1 low dose; Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Experimental: Group 0b; Single dose of 7.5 lg EID50 of H1N1pdm09 vaccine component	Biological: Corfluvec component 2 low dose; Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Experimental: Group 0c; Single dose of 8.0 lg EID50 of H3N2 vaccine component	Biological: Corfluvec component 1 high dose; Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Experimental: Group 0d; Single dose of 8.3 lg EID50 of H1N1pdm09 vaccine component	Biological: Corfluvec component 2 high dose; Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Experimental: Group 1a; Low dose vaccine, two components received three weeks apart	Biological: Corfluvec low dose; Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
Experimental: Group 1b; High dose vaccine, two components received three weeks apart	Biological: Corfluvec high dose; Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
Placebo Comparator: Group 1c; Placebo, two doses received three weeks apart	Biological: Placebo; Participants will receive two intranasal injections of placebo three weeks apart
Experimental: Group 2a; High dose vaccine, two components received three weeks apart	Biological: Corfluvec high dose; Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
Placebo Comparator: Group 2b; Placebo, two doses received three weeks apart	Biological: Placebo; Participants will receive two intranasal injections of placebo three weeks apart

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs)	Number of participants with AEs and SAEs including those of particular interest: immediate AEs (allergic reactions) occurring within 2 h after vaccination;; post-vaccination reactions between 2 h and a subsequent 7 days;; other AEs including unexpected clinical manifestations of a local and systemic nature occurring on the day of vaccination and the following 7 days;; deviations of laboratory parameters of analyzes of blood and urine samples and data from instrumental studies (ECG) obtained on Days 3, 7, 23 and 27;; all SAEs occurring up to 3 weeks after each vaccination; late AEs occurring after study Day 42 through Day 180±5;; influenza A virus shedding detected by rapid test in nasal swab samples	Throughout the study, average of 6.5 months
Level of SARS-CoV-2 antigen specific cytokine producing T-cells	Change from baseline in the level of cytokine producing T-cells upon in vitro stimulation of PBMC with SARS-CoV-2 N protein peptide epitopes measured by ICS/ELISPOT	Throughout the 42±2 study days
Level of SARS-CoV-2 antigen specific cytokine release in whole blood assay	Change from baseline in the cytokine concentration in whole-blood cytokine release assay upon in vitro stimulation with SARS-CoV-2 N protein peptide epitopes	Throughout the 42±2 study days
Level of SARS-CoV-2 antigen specific mucosal and systemic IgA and IgG antibody	Change from baseline in the levels of IgA and IgG antibody to SARS-CoV-2 N protein measured in ELISA in saliva/nasal secret and serum	Throughout the 42±2 study days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of responders to vaccination according to the fold increase in the level of specific T-cell response	Proportion of participants exhibiting significant increase in the level of specific T-cell response to SARS-CoV-2 N protein after vaccination in comparison to baseline. The increase in the parameter is considered significant if it exceeds the specified range, which is a 95% CI for mean value of parameter fold change in the Placebo group at assessment day compared to Day 1	Days 7, 21, 27, 42±2
Seroconversion rate of SARS-CoV-2 antigen specific antibody	Proportion of participants who have at least a 4-fold increase in post-vaccination antibody titers in comparison to baseline	Days 21, 42±2

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Concentration of cytokines in nasal secrets after vaccination	Change from the baseline in the concentration of cytokines in nasal secrets measured in ELISA/Multiplex system	Throughout the first 48h of the study
Influenza specific local and systemic antibody immune response	Change from baseline in the uiters of influenza specific antibodies in serum and saliva/nasal secret measured in ELISA, HI, MNA and corresponding seroconversion rates.	Throughout the 42±2 study days
SARS-CoV-2 and influenza specific antibody and T-cell immune response (follow-up)	Specific systemic antibody and T-cell immune response to SARS-CoV-2 N protein and influenza viruses (A/H1N1pdm09, A/H3N2) measured in ELISA, ISC/ELISPOT, whole-blood cytokine release assay.	Days 90±3, 180±5
Efficacy against symptomatic COVID-19 and influenza	Number of laboratory-confirmed symptomatic cases of COVID-19 and influenza	Throughout the study, average of 6.5 months

Collaborators and Investigators

• Sponsor: Tatyana Zubkova
• Collaborators: St. Petersburg State Pavlov Medical University; MDP-CRO, LLC

Study record dates

Study Major Dates

• Study Start (Actual): September 13, 2022
• Primary Completion (Actual): December 30, 2022
• Study Completion (Actual): May 31, 2023

Study Registration Dates

• First Submitted: January 17, 2023
• First Submitted That Met QC Criteria: January 23, 2023
• First Posted (Actual): January 25, 2023

Study Record Updates

• Last Update Posted (Actual): April 18, 2024
• Last Update Submitted That Met QC Criteria: April 17, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: vaccine; COVID-19; influenza vector
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: KFV-I/II-01/2022

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No